Kyongbo Pharmaceutical Co Ltd

Kyongbo Pharmaceutical Co Ltd has a liquidity profile that shows a current ratio of 1.08 and a debt-to-equity ratio of 0.87, indicating moderate leverage. The company's liquidity is assessed as medium, with negative net cash after subtracting total debt. The price-to-book ratio of 1.04 suggests that the company's market value is closely aligned with its book value. The company's profitability is weak, with a return on equity of 0.0013 and a return on assets of 0.0006, both significantly below the industry median for pharmaceutical companies. The operating margin is 1.33%, and the net margin is 0.07%, which are also below the industry average. The company's gross margin of 38.75% is relatively strong but insufficient to offset the low net profitability. Kyongbo Pharmaceutical Co Ltd's revenue is distributed across three segments: API Business, Finished Pharmaceutical Product Business, and Other business. The API Business segment is the largest contributor, followed by the Finished Pharmaceutical Product Business. The company's geographic exposure is primarily concentrated in South Korea, with no significant international revenue disclosed in the latest financials. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The free cash flow is negative at -29.4 billion KRW, and capital expenditures are high at -41.6 billion KRW, indicating significant reinvestment in the business. The operating cash flow of 7.5 billion KRW is positive but insufficient to cover the capital outlay. The risk assessment for Kyongbo Pharmaceutical Co Ltd highlights medium liquidity risk and low dilution risk. The company has a low probability of near-term dilution, with no significant dilution sources identified in the latest filings. The risk assessment also notes the potential for regulatory and geopolitical risks, particularly in the pharmaceutical industry, but no specific events are cited in the latest data. Recent events and filings for Kyongbo Pharmaceutical Co Ltd include the latest financial snapshot, which shows a revenue of 264.1 billion KRW and a net income of 182.3 million KRW. The company's financial health is further detailed in the valuation and risk assessments, which provide a comprehensive view of its current position in the market.